PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the… Read More
The drug candidate PN6047 from PharmNovo is an entirely new drug. The substance is a selective delta opioid, a so-called DORA (delta opioid receptor agonist),… Read More
PharmNovo has submitted a Clinical Trial Application (CTA) for its lead candidate for treatment of neuropathic pain.
PharmNovo AB is pleased to announce that a Clinical Trial Application (CTA) has been submitted to the Swedish Medical Products Agency (MPA) as well as… Read More